Indications
Proguanil is utilized for both the causal prevention and suppression of malaria. It is effective against susceptible strains of Plasmodium falciparum as well as other Plasmodium species present in various geographical regions.
Pharmacodynamics
Proguanil is a biguanide derivative that is metabolized into an active compound known as cycloguanil. Its antimalarial effect is primarily due to the inhibition of the parasitic enzyme, dihydrofolate reductase. Proguanil possesses both causal prophylactic and suppressive abilities against P. falciparum and is proficient in treating·helps in mitigating·hough its action is slower when compared to 4-aminoquinolines.
Absorption
Upon oral administration within a dosage rang·humans.
Metabolism
Proguanil undergoes variable metabolism in the liver, primarily through cytochrome P450 isoenzymes, resulting·he formation of the active metabolite, cycloguanil. This metabolism can significantly affect clinical outcomes, particularly in individuals categorized as poor metabolizers, such as some populations in Asia and Africa who are at greater risk for malaria. In these individuals, prophylactic treatment with Proguanil may not achieve sufficient therapeutic levels of cycloguanil, even with repeated dosing, potentially reducing its efficacy.
Mechanism of Action
Proguanil functions by inhibiting the dihydrofolate reductase enzyme in plasmodia, which is crucial in halting the biosynthesis of purines and pyrimidines. These nucleotides are fundamental components necessary for DNA synthesis and cell proliferation. As a result, this inhibition causes an interruption in nuclear division during the formation of schizonts in both erythrocytes and the liver.
